Progress in Mechanism-based Diagnosis and Treatment of Tuberculosis Comorbid with Tumor

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Feb 1

PMID 38298194

Authors

Chuan Wang

Rong-Qi Zou

Guo-Zhong He

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) and tumor, with similarities in immune response and pathogenesis, are diseases that are prone to produce autoimmune stress response to the host immune system. With a symbiotic relationship between the two, TB can facilitate the occurrence and development of tumors, while tumor causes TB reactivation. In this review, we systematically sorted out the incidence trends and influencing factors of TB and tumor, focusing on the potential pathogenesis of TB and tumor, to provide a pathway for the co-pathogenesis of TB comorbid with tumor (TCWT). Based on this, we summarized the latest progress in the diagnosis and treatment of TCWT, and provided ideas for further exploration of clinical trials and new drug development of TCWT.

References

Xie Y, Su N, Zhou W, Lei A, Li X, Li W . Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor. Cancer Manag Res. 2021; 13:7517-7526. PMC: 8491869. DOI: 10.2147/CMAR.S326349. View

Askling J, Ekbom A . Risk of non-Hodgkin's lymphoma following tuberculosis. Br J Cancer. 2001; 84(1):113-5. PMC: 2363601. DOI: 10.1054/bjoc.2000.1551. View

Kuo C, Lo C, Chung F, Lee K, Lin S, Wang C . Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. PLoS One. 2012; 7(3):e33226. PMC: 3306389. DOI: 10.1371/journal.pone.0033226. View

Sharma R, Kaur A, Sharma A, Dilbaghi N, Sharma A . Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis. Curr Drug Targets. 2015; 18(1):72-86. DOI: 10.2174/1389450116666150804110238. View

Chen G, Guo L, Yang S, Ji D . Cancer risk in tuberculosis patients in a high endemic area. BMC Cancer. 2021; 21(1):679. PMC: 8190842. DOI: 10.1186/s12885-021-08391-6. View

Sun H, Pan L, Jia H, Zhang Z, Gao M, Huang M . Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection. Front Microbiol. 2018; 9:1267. PMC: 6008387. DOI: 10.3389/fmicb.2018.01267. View

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

Roquilly A, Jacqueline C, Davieau M, Molle A, Sadek A, Fourgeux C . Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nat Immunol. 2020; 21(6):636-648. DOI: 10.1038/s41590-020-0673-x. View

Suresh K, Naidoo J, Lin C, Danoff S . Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest. 2018; 154(6):1416-1423. PMC: 6335259. DOI: 10.1016/j.chest.2018.08.1048. View

10.

Cha S, Shin K, Lee J, Lee S, Kim C, Park J . The clinical course of respiratory tuberculosis in lung cancer patients. Int J Tuberc Lung Dis. 2009; 13(8):1002-7. View

11.

Hughes P, Caenepeel S, Wu L . Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends Immunol. 2016; 37(7):462-476. DOI: 10.1016/j.it.2016.04.010. View

12.

Kumar D, Ronald L, Romanowski K, Rose C, Shulha H, Cook V . Risk of active tuberculosis in migrants diagnosed with cancer: a retrospective cohort study in British Columbia, Canada. BMJ Open. 2021; 11(3):e037827. PMC: 7929860. DOI: 10.1136/bmjopen-2020-037827. View

13.

Fan N, Gao J, Liu Y, Song W, Zhang Z, Gao C . Label-free quantitative mass spectrometry reveals a panel of differentially expressed proteins in colorectal cancer. Biomed Res Int. 2015; 2015:365068. PMC: 4324820. DOI: 10.1155/2015/365068. View

14.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

15.

Nakajima T, Fujikawa T, Takagi Y, Shiroiwa H, Fujiwara H . [A Case of Concomitant Administration of Anti-Cancer Drug and Anti-Tuberculosis Drug for Pulmonary Tuberculosis Developed during Postoperative Chemotherapy for Gastric Cancer]. Gan To Kagaku Ryoho. 2021; 48(7):959-962. View

16.

Ugel S, De Sanctis F, Mandruzzato S, Bronte V . Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 2015; 125(9):3365-76. PMC: 4588310. DOI: 10.1172/JCI80006. View

17.

Hirashima T, Tamura Y, Han Y, Hashimoto S, Tanaka A, Shiroyama T . Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study. BMC Cancer. 2018; 18(1):975. PMC: 6186130. DOI: 10.1186/s12885-018-4889-1. View

18.

Liebenberg D, Gordhan B, Kana B . Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022; 12:943545. PMC: 9538507. DOI: 10.3389/fcimb.2022.943545. View

19.

Wessels G, Hesseling P, Gie R, Nel E . The increased risk of developing tuberculosis in children with malignancy. Ann Trop Paediatr. 1992; 12(3):277-81. DOI: 10.1080/02724936.1992.11747585. View

20.

Gupta N, Hatoum H, Dy G . First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine. 2014; 9:209-21. PMC: 3875520. DOI: 10.2147/IJN.S41770. View